Roche's $3.1 billion investment layout: another pharmaceutical giant enters the weight loss drug market
网事大话每
发表于 2023-12-5 19:21:19
1296
0
0
Analysts estimate that the global weight loss market will reach a size of up to $100 billion. Swiss pharmaceutical giant Roche recently announced that it has agreed to acquire unlisted American weight loss drug developer Carmot Therapeutics for an initial price of $2.7 billion. This means that it entered the weight loss drug market by acquiring "Fast Track", challenging weight loss drug giants Novo Nordisk and Lilly. Roche stated that according to the trading contract, the transaction is expected to be completed in the first quarter of 2024. If Carmot Therapeutics achieves individual milestones with its drugs, the company's shareholders can receive $400 million.
Multiple giants are intensifying their layout in the weight-loss drug market
After the transaction is completed, Roche will acquire all current clinical and preclinical assets of Carmot Therapeutics, and employees of Carmot Therapeutics will also join Roche's pharmaceutical department. For Roche, this transaction marks the company's return to the GLP-1 field. Previously, in 2018, Roche abandoned the GLP-1 field when its subsidiary sold a patent for an experimental drug to Lilly for a prepayment of $50 million.
It is reported that Carmot Therapeutics is an American biotechnology company in the clinical stage. Last month, Carmot Therapeutics just submitted its prospectus for listing on NASDAQ and is now being acquired by Roche. Public information shows that Carmot Therapeutics is committed to the development of metabolic disease drugs. At present, the company's products include subcutaneous and oral incretin drugs, which help to treat obesity in diabetes and non diabetes patients and multiple preclinical plans.
In the second half of this year, there were frequent acquisition transactions in the weight loss drug market. In July of this year, Lilly acquired the unlisted Versanis for up to $1.93 billion to further expand its weight loss drug product line; Last month, AstraZeneca agreed to purchase exclusive rights to the development and commercialization of oral GLP-1 weight loss products produced by Chinese biotech company Eccogene for up to $2 billion.
Weight loss pills are selling well, and Novo Nordisk's net profit increased by 43% year-on-year in the first half of the year
Novo Nordisk's previously released financial report for the first half of 2023 showed that during the reporting period, its net sales were 107.667 billion Danish kroner, compared to 83.296 billion Danish kroner in the same period last year, a year-on-year increase of 29%; The net profit was 39.242 billion Danish kroner, compared to 27.528 billion Danish kroner in the same period last year, an increase of 43% year-on-year. Novo Nordisk has raised its annual profit and sales expectations. The CEO of the company said in a statement that Novo Nordisk had raised its annual performance forecast based on the strong demand of the market for diabetes and obesity drugs. The company now serves more patients than ever before.
From the perspective of product line, the sales of diabetes and obesity care increased by 36% to DKK 99 billion, of which the sales of diabetes drug GLP-1 increased by 49%, and the sales of obesity care drugs surged by 158% to DKK 18.1 billion.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- High energy ahead! The "Seven Giants" of the US stock market are about to announce their financial reports, and the shocking data is coming
- AI chip giant NVIDIA's market value exceeds Apple's, TSMC previously stated that AI demand is' just beginning '
- Chip giant TSMC faces unexpected changes! What happened?
- Huang Renxun makes a major announcement! Nvidia and SoftBank collaborate, SoftBank accelerates AI layout
- Tesla FSD Big News: Billion Dollar Automotive Giant Shocking!
- Suddenly changed! Big news from chip giants! Samsung Electronics' stock price rises
- AI giant, big news! I may be delisted next week! I may be delisted next week!
- Novo Nordisk's weight loss drug, semaglutide, is launched today and will be sold through multiple channels
- The latest holdings of leading global asset management giants in Chinese concept stocks have been exposed
- 80 billion Shanghai data giant raises 12 billion to expand data center
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏